The prevalance of Gestational Diabetes Mellitus (GDM) is increasing worldwide. It is estimated that 21 million women develop gestational diabetes out of which 1 in 7 births are affected. Women who have been previously diagnosed as GDM are at higher risk of developing diabetes in subsequent pregnancies and Type 2 Diabetes Mellitus (T2DM) later in life. Babies born to mothers with gestational diabetes also have a higher risk of developing type 2 diabetes in their teens or early adulthood. Instead of risk stratification universal screening is essential in all pregnant women. Tight glycaemic targets are required for optimal maternal and foetal outcome. This article outlines the importance of pre-pregnancy counseling, antenatal management, screening and treatment of Hyperglycaemia in Pregnancy (HIP).
Keywords: Pre-Pregnancy Counseling, Antenatal Care, Gestational Diabetes Mellitus, Blood Glucose Screening, Type 2 Diabetes, Lifestyle & Diet in Pregnancy.
Gestational diabetes mellitus (GDM) is defined as any degree of glucose intolerance with onset or first recognition during pregnancy.1 Hyperglycaemia in pregnancy may be classified as gestational diabetes mellitus, i.e. first detected during pregnancy or pre-diabetes diagnosed prior to pregnancy. It was first recognized clinically in 1824 in Germany.2 About hundred years back (1916), Joslin reported a case of GDM which resolved with delivery, and reappeared later in life. 3 Later, an association of GDM with adverse perinatal outcome was recognized in early 1960\\\'s by Hoet, 4 First standardized criteria for GDM diagnosis was developed in Boston City Hospital by O\\\'Sullivan. Later, this 100g OGTT test procedure continued in clinical use for four decades with some modifications.5
Prevalence of GDM
The incidence of GDM is increasing.6-8 Globally 415 million people are affected by diabetes.9 As the prevalence of this metabolic disorder is increasing in the younger generation, so more women are affected during pregnancy.10 According to an estimate 21 million women or 16.2% of live births have some form of hyperglycaemia in pregnancy. Another 54 million women are affected by impaired glucose tolerance (IGT) with a potential to develop GDM if they become pregnant. Thus over 76 million women in the reproductive age are at risk of their pregnancy being complicated with pre gestational (existing) diabetes or gestational diabetes.10 Sedentary lifestyle, stress of urbanization, bad eating habits, increasing age of marriage and high parity, contribute towards increasing prevalence of diabetes in pregnancy.11 The highest raw and age adjusted prevalence from South East Asia (SEA) and Middle East North Africa (MENA) region is about 46% affecting 10.4 million live births.9,10 Globally 88% of women who had high blood glucose during pregnancy were from low and middle income countries.12 Despite the second highest prevalence of diabetes in MENA region, a total of only USD 17.1- 27.7 billion was spent on diabetes healthcare in 2015. This is equivalent to approximately 15% of the total health budget. Health expenditure on diabetes in this region accounts for just 2.5% of global spending on the disease.10 This does not seem enough to adequately treat all people with the disease.
Importance of Screening During Gestational Diabetes
Universal screening (testing all pregnant women) is more relevant to Asian population including Pakistani women who are considered to be at high risk.12 HIP usually is asymptomatic, women who are not screened for blood glucose estimation; will not be diagnosed and therefore will not be treated. This unrecognized and therefore untreated HIP can have foetal, neonatal and maternal complications in addition to the development of T2DM in the mother in later life and in the child in early adolescent life. So the diagnosis and management of hyperglycaemia in pregnancy may be done according to available resources as compared to no or poor care,13 despite socioeconomic, cultural and health system constrains.
Screening for GDM
The global controversy continues about the best screening and diagnostic methods for GDM.14 WHO (2013) and International Association of Diabetes and Pregnancy Study Group (IADPSG 2010) has approved single-step 75G OGTT criteria.15 In IADPSG criteria venous blood sample is taken after 08 hours of overnight fasting. Thereafter 75G of anhydrous glucose dissolved in 250cc water is given to drink in 05 minutes. Venous blood samples are drawn at 1 and 2 hours after glucose load. 15
The recommended blood glucose targets according to IADPSG for diagnosis of hyperglycaemia in pregnancy14 are as under:
Fasting: 92 mg/dl
01 hr. post-prandial: 180 mg/dl
02 hours. post-prandial: 153 mg/dl
In IADPSG criteria an increased number of women up to 18 - 25% may be diagnosed as having GDM. 16 This is due to lower diagnostic levels of glucose thresholds and only a single abnormal value is recommended as conclusive for diagnosis.
Most women come to antenatal clinics in non-fasting state; they can be screened by Diabetes in pregnancy study group India, (DIPSI) method.17 A non- fasting oral glucose tolerance test (OGTT) using 75 G glucose solution is given to drink irrespective of the last meal. A venous blood sample is tested 2 hours after the oral glucose load. In DIPSI method the cut off for screening and diagnostic level of blood glucose is 140 mg/dl.15,17
Frequency of Glucose Monitoring
The guidelines regarding frequency of blood glucose testing are equivocal. American Diabetes Association (ADA) encourages pre and postprandial monitoring of blood glucose but does not recommend a specific frequency of testing.18 However, one fasting and three postprandial (two hours post meal) self-monitoring of blood glucose (SMBG) are recommended for women with hyperglycaemia in pregnancy (HIP) to prevent macrosomia.19,20 In low resource settings one postprandial SMBG with documented relation to timing of meal can help in management of HIP.
Target Level of Blood Glucose in Pregnancy
It must be emphasized that diagnostic levels of blood glucose is not the same as the control levels of blood glucose (after the diagnosis of diabetes is confirmed). The aim of therapy is to achieve normoglyacemia without undergoing hypoglycaemic episodes during pregnancy.
Pathophysiology of GDM
In non-obese women insulin sensitivity decreases by 40% during normal pregnancy.21 As a result insulin production is increased due to pancreatic beta cell hyperplasia. Increased insulin resistance during pregnancy is because of contra-insulin placental hormones like human placental lactogen, human chorionic somatotrophin and visceral adiposity. Normally blood glucose levels in pregnancy are lower due to continuous foetal consumption, increased glycogen storage and decreased hepatic glucose output. Women who develop hyperglycaemia during pregnancy because of high insulin resistance and obesity, the compensatory mechanisms fail to meet the increasing demands with advancing gestation and result in manifestation of diabetes.
Risk associated with Hyperglycaemia in Pregnancy
Women who are not screened and thus remain undiagnosed for diabetes during pregnancy have greater risk of pregnancy complications like pregnancy induced hypertension (PIH), repeated vaginal candidal infections, polyhydramnios and increased risk of caesarean births but also run the risk of developing type 2 diabetes in later life.11 The increased risk of foetal congenital anomalies, miscarriages, preterm births, macrosomia and iatrogenic prematurity are well known intra uterine complications. In newborns the risk of hypoglycaemia, hypocalcaemia, hyperbilirubinaemia can be reduced if mother is screened for diabetes during pregnancy and glycaemic control is appropriately instituted.
Pre-Pregnancy Care (PPC)
Despite the proven benefits of PPC the compliance is poor. PPC is the main principle of management for women with pre-existing hyperglycaemia or previous history of GDM. The aim is to optimize glycaemic control 03-06 months prior to planning next pregnancy. Attention to diet, exercise and counseling regarding weight reduction and normalizing BMI prior to conception may have beneficial effects on diabetes control and improve insulin resistance.
Medications like ACE inhibitors, ARBs and statins should be discontinued since these medications have known teratogenic effects. Instead Methyldopa is a safer antihypertensive in pregnancy. In women with long standing diabetes retinal, renal, neuropathic and cardio vascular complications need combined medical care.
Antenatal obstetric management should include frequent antenatal visits over and above which is required for a non-diabetic pregnancy. Frequent foetal ultrasound monitoring including second trimester anomaly scan to exclude cardiac, skeletal and neural tube defects. Third trimester growth scan are essential to rule out macrosomia or dysmaturity. Attention to blood pressure monitoring due to increased incidence of pre-eclampsia, urinalysis to exclude asymptomatic bacteuria, treatment of vaginal candidal infections. In view of iatrogenic prematurity and possibility of antenatal steroids (with increase in insulin dosage), an up titration of insulin with increasing gestation are few of the important antenatal management strategies. Strict glycaemic control throughout antenatal period with diet, lifestyle and or insulin is required. Decision regarding mode of delivery should be individualized according to estimated foetal weight (macrosomia), glycaemic control, medical and obstetrical history.
Life style modification
Lifestyle modification, diet, exercise and weight management are important pre-pregnancy and antenatal interventions. An individualized lifestyle intervention reduces the incidence of GDM by 39% in high risk pregnant women.22
Medical Nutritional Therapy
The overall goal of dietary intervention in pregnancy with diabetes is meant to reduce the risk of perinatal complications e.g. macrosomia associated with hyperglycaemia. To prevent excessive maternal weight gain, approx. 2000 - 2050 calories is required (irrespective of their BMI) to maintain euglycaemia, control maternal weight gain, and neonatal birth weight around 3.5 Kg.23,24 Food having low glycaemic index (<70) helps in reducing glucose excursions.25 High soluble fibre diets (up to 28 g/day) are recommended in pregnancy as it has low glycaemic index.26The dietary management can be achieved by using culturally appropriate model or color coding of food plate in low resource settings. Dietary regulations/ modifications and 30 minutes of physical activity may reduce glucose levels up to 23 mg/dl.27
Macronutrients and Micronutrients
An evidence-based recommendation for optimum nutritional intervention in pregnancy is scarce. A minimum of 175 grams of carbohydrates intake per day28 or 40% of the carbohydrate are said to reduce hyperglycaemia.29 It should be distributed throughout the day in three meals and three snacks.30 Fish is a rich source of lean protein and contains three omega fatty acids. It also contains traces of mercury which readily crosses the placental barrier and is reported to damage foetal nervous system. However, shrimps, canned tuna, salmon have low levels of mercury and women can have approximately 250 - 300 grams a week (two average meals).30 For a positive impact on the metabolic goals of GDM,31 in addition to macronutrients, some micronutrients such as vitamin D (400 - 1000 units/day), folate (400 micrograms up to 12 weeks of gestation to prevent foetal neural tube defects), B6, B12, calcium (800 units/day), iron (100-200 mg of oral elemental iron per day), z nc and omega 3 fatty acid are important for foetal development and to prevent maternal postpartum depression.30 Extreme caloric restriction less than 1500 calories per day may increase the risk of ketonemia in pregnancy with Type 1 Diabetes Mellitus (T1DM).13 An evening snack may prevent ketosis overnight.
Physical activity leads to increase glucose uptake into skeletal muscles, 32 improves insulin action and may change distribution of body fat and reduction in visceral fat.33 Arm exercises while seated in a chair for 10 minutes after each meal is recommended in women with GDM. 32 Physical activity of moderate intensity of about 20 minutes per day, low caloric diet and weight loss may reduce the risk of progression to T2DM in women with history of GDM.33-35 Each 5 kg increment of weight gain after GDM pregnancy is associated with a 27% higher risk of future development of T2DM.33
Medical Therapy for HIP
When diet and physical activity are not sufficient to control hyperglycaemia in pregnancy, insulin is considered as gold standard of therapy. Requirement of insulin usually changes in each trimester. Short acting analogues Lispro and Aspart and long acting Detemir are considered safe to be used in pregnancy.13 In case of poor glycaemic control and non-compliance to medical therapy, HbA1c levels may be tested as per trimester-specific recommendations.36 Use of oral hypoglycaemic drugs (OHDs) like Metformin and Glyburide (Glibenclamide) are increasingly considered as a sole or adjuvant to insulin therapy. As a result, use of glyburide increased from about 7% to 65% in ten years period (from 2000 to 2011) since 2007.26,37-39 According to a systematic review and meta-analysis published in BMJ 2015,40 glyburide seems inferior to both Insulin and Metformin. While a combination of Insulin and Metformin performs slightly better than metformin alone.
Considering the high prevalence of hyperglycaemia in pregnancy, universal screening of all pregnant women should be recommended. 7 The importance of early diagnosis of hyperglycaemia in pregnancy is crucial to avoid fosetal and maternal complications and future development of Type 2 diabetes in both mother and child.
1.Metzger BE, Coustan DR, Organizing Committee. Summary and recommendations of the fourth international workshop-conference on gestational diabetes mellitus. Diabetes care. 1998; 21: B161-7.
2.Hadden DR, Hillebrand B. The first recorded case of diabetic pregnancy (Bennewitz HG, 1824, university of Berlin). Diabetologia 1989; 32: 625.
3.Joslin EP: The treatment of diabetes mellitus. Can Med Assoc J 1916; 6: 673-84.
4.Hoet JP, Lukens FD. Carbohydrate metabolism during pregnancy. Diabetes 1954; 3: 1-12.
5.O\\\'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964; 13: 278-85.
6.Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012; 307: 491-7.
7.Coustan DR, Lowe LP, Metzger BE, Dyer AR, International Association of Diabetes and Pregnancy Study Groups. The hyperglycemia and adverse pregnancy outcome (HAPO) study: paving the way for new diagnostic criteria for gestational diabetes mellitus. Am J Obstet Gynecol 2010; 202: 654.e1-e6.
8.Dabelea D, Snell-Bergeon JK, Harts?eld CL, Bischoff KJ, Hamman RF, McDuf?e RS, et al. Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: kaiserpermanente of Colorado GDM screening program. Diabetes Care 2005; 28: 579-84.
9.International Diabetes Federation. Diabetes atlas. 7th ed. Brussels: International Diabetes Federation, 2015.
10.Sacks DB. Diagnosis of gestational diabetes mellitus: it is time for international consensus. Clin Chem 2014; 60: 141-3.
11.Fetita LS, Sobngwi E, Serradas P, Calvo F, Gautier JF. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab 2006; 91: 3718-24.
12.Neilsen KK, de Courten M, Kapur A. The urgent need for universally applicable simple screening procedures and diagnostic criteria for gestational diabetes mellitus - lessons from projects funded by the world diabetes foundation. Glob Health Action 2012; 5: 17277.
13.Hod M, Kapur A, Sacks DA, Hadar E, Agarwal M, Di Renzo GC, et al. The international federation of gynecology and obstetrics (FIGO) initiative on gestational diabetes mellitus: a pragmatic guide for diagnosis, management, and care. Int J Gynaecol Obstet 2015; 131 (Suppl 3): S173-211.
14.Metzger BE, Gabbe SG, Persson B, et al., International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 2010; 33: 676-82.
15.World Health Organization. Diagnostic criteria and classification of hyperglycaemia first detected in pregnancy. Geneva, WHO, 2013.
16.Sacks DA, Hadden DR, Maresh M, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel - recommended criteria: the hyperglycemia and adverse pregnancy outcome (HAPO) study. Diabetes Care 2012; 35: 526-8.
17.Anjalakshi C, Balaji V, Balaji MS, Ashalata S, Suganthi S, Arthi T, et al. A single test procedure to diagnose gestational diabetes mellitus. Acta Diabetol 2009; 46: 51-4.
18.American Diabetes Association. Standards of medical care in diabetes - 2015. Diabetes Care 2015; 38(Suppl 1): S1-S90.
19.HAPO Study Cooperative Research Group. The hyperglycemia and adverse pregnancy outcome (HAPO) study. Int J Gynaecol Obstet 2002; 78: 69-77.
20.Metzger BE, Lowe LP, Dyer AR, et al, HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 2008; 358: 1991-2002.
21.Catalano PM, Huston L, Amini SB, Kalhan SC. Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 1999; 180: 903-16.
22.Koivusalo S, Rönö K, Klemetti M, Roine R, Lindström J, Erkkola M et al. Gestational diabetes mellitus can beprevented by lifestyle intervention: the Finnish gestational diabetes prevention study (RADIEL)- a randomized controlled trial. Diabetes Care 2016; 39: 24-30.
23.Foyett JP. Management of obesity. Prim Care Rep 2000; 6: 19.
24.Snyder J, Gray-Donald K, Koski KG. Predictors of infant birth weight in gestational diabetes. Am J Clin Nutr 1994; 59: 1409-14.
25.Institute of Medicine. Dietary reference intakes: energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein, and amino acids. Washington, DC: National Academies Press; 2002: 389.
26.National Collaborating Centre for Women\\\'s and Children\\\'s Health (UK). Diabetes in pregnancy: management of diabetes and its complications from preconception to the postnatal period. NICE Clinical Guideline, No.63. London: RCOG Press; 2008.
27.Avery MD, Walker AJ. Acute effect of exercise on blood glucose and insulin levels in women with gestational diabetes. J Matern Fetal Med 2001; 10: 52-8.
28.Thomas AM, Gutierrez YM. American dietetic association guide to gestational diabetes mellitus. Chicago IL: American Dietetic Association; 2005.
29.Major CA, Henry MJ, De Veciana M, Morgan MA. The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes. Obstet Gynecol 1998; 91: 600-4.
30.Thomas A, Duarte-Gardea M. Preconception and prenatal nutrition. In: Samour PQ, King K. Pediatric Nutrition. 4th ed. Burlington, MA: Jones & Bartlett Learning; 2010.
31.Reader D, Splett P, Gunderson EP, Diabetes Care and Education Dietetic Practice Group. Impact of gestational diabetes mellitus nutrition practice guidelines implemented by registered dietitians on pregnancy outcomes. J Am Diet Assoc 2006; 106: 1426-33.
32.ColbergSR, Sigal RJ, Fernhall B, Regensteiner JG, Blissmer BJ, Rubin RR, et al. Exercise and type 2 diabetes: the American college of sports medicine and the American diabetes association: joint position statement. Diabetes care 2010; 33: e147-67.
33.Bao W, Yeung E, Tobias DK, Hu FB, Vaag AA, Chavarro JE, et al. Long-term risk of type 2 diabetes mellitus in relation to BMI and weight change among women with a history of gestational diabetes mellitus: a prospective cohort study. Diabetologia 2015; 58: 1212-9.
34.Department of Health and Human Services. Physical activity guidelines for Americans. Washington, DC, 2008.
35.Ratner RE, Christophi CA, Metzger BE, et al. Diabetes Prevention Program Research Group. Prevention of diabetes in women with a history of gestational diabetes: effects of metformin and lifestyle interventions. J Clin Endocrinol Metab 2008; 93: 4774-9.
36.O\\\'Connor C, O\\\'Shea PM, Owens LA, Carmody L, Avalos G, Nestor L, et al. Trimester-specific reference intervals for haemoglobin A1c (HbA1c) in pregnancy. Clin Chem Lab Med 2011; 50: 905-9.
37.Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the fifth international workshop-conference on gestational diabetes mellitus. Diabetes Care 2007; 30 (Suppl 2): S251-60.
38.Hunt KJ, Schuller KL. The increasing prevalence of diabetes in pregnancy. Obstet Gynecol Clin North Am 2007; 34: 173-99.
39.Committee on Practice Bulletins- Obstetrics. Practice bulletin no. 137: gestational diabetes mellitus. Obstet Gynecol 2013; 122: 406-16.
40.Balsells M, García-Patterson A, Solà I, Roqué M, Gich I, Corcoy R. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. BMJ 2015; 350: h102.